Akari Therapeutics (AKTX) Fundamental Analysis: Revenue, Earnings & Valuation

8.21 / 10

Outperform

Fundamentals rate Outperform with an 8.2/10 score. Strengths include high interest coverage, favorable PB‑ROE, strong asset and revenue multiples, and rapid inventory turnover. Caution arises from elevated current‑liabilities ratio and high long‑term debt to working‑capital.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight35.41%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.49%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-4.04%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value68.61

Score1/3

Weight-5.65%

1M Return-1.69%

PB-ROE

Value-0.35

Score3/3

Weight44.60%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value26.96

Score0/3

Weight-15.38%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-4.10%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.20%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-3.88%

1M Return-1.13%

Asset-MV

Value-0.49

Score2/3

Weight52.36%

1M Return11.12%

Is AKTX fundamentally strong?

AKTX scores 8.21/10 on fundamentals and holds a Discounted valuation at present. Backed by its -53.43% ROE, 0.00% net margin, -0.37 P/E ratio, 0.25 P/B ratio, and 0.00% earnings growth, these metrics solidify its Outperform investment rating.